Scarica l'app Stockscreener
30.48
0.43%
0.13
Dopo l'orario di chiusura:
30.31
-0.17
-0.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AMPH Giù?
Forum
Previsione
Amphastar Pharmaceuticals Inc Borsa (AMPH) Ultime notizie
Amphastar Pharmaceuticals (NASDAQ:AMPH) Raised to "Buy" at Needham & Company LLC - MarketBeat
Amphastar and Anji make licence agreement for three new peptides - Yahoo Finance
Amphastar Pharmaceuticals’ Mixed Earnings Call Highlights - TipRanks
Amphastar Pharmaceuticals Gets Upgrade to Buy at Needham on AMP-002 Approval - AInvest
Amphastar Pharmaceuticals Upgraded to Buy by Needham Analyst - AInvest
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know - Yahoo Finance
Amphastar Pharmaceuticals Secures FDA Approval for Iron Sucrose Injection, Sets Sights on Major Sales Momentum - AInvest
Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum - Yahoo Finance
Amphastar raised to Buy at Needham on iron sucrose injection approval - Seeking Alpha
Amphastar stock gains after licensing deal for three peptide therapies By Investing.com - Investing.com Canada
Needham upgrades Amphastar Pharmaceuticals stock to Buy on iron sucrose approval - Investing.com Canada
Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals - insights.citeline.com
Amphastar licenses three peptide therapies in oncology, ophthalmology deal By Investing.com - Investing.com South Africa
Amphastar Pharmaceuticals Enters Strategic Licensing Agreement - TipRanks
Amphastar gets FDA nod for generic iron sucrose injection - MSN
Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. - ACCESS Newswire
Amphastar's $453M Breakthrough: Exclusive Rights to Revolutionary Cancer and Eye Disease Peptide Therapies - Stock Titan
AMPH Q2 Deep Dive: BAQSIMI Momentum, Margin Pressures, and Pipeline Milestones - Yahoo Finance
Primatene Mist Sales Flat As Amphastar Plans Production Expansion To Support Pipeline - insights.citeline.com
FDA Approvals for Iron Sucrose Products by Viatris, Amphastar Pharmaceuticals - AInvest
Amphastar Pharmaceuticals (AMPH) stock surges 10.4% on FDA approval for generic Iron Sucrose Injection treatment for iron deficiency anemia. - AInvest
Why Is Amphastar Pharmaceuticals (AMPH) Stock Soaring Today - FinancialContent
FDA OKs Generic Iron Sucrose for CKD Anemia - Conexiant
Amphastar Soars 14.36% on FDA Approval: A Game-Changer or Fleeting Rally? - AInvest
Amphastar stock rises after FDA approves generic iron sucrose injection By Investing.com - Investing.com Canada
FDA approves Amphastar’s iron sucrose injection for anemia treatment By Investing.com - Investing.com Australia
Amphastar Announces FDA Approval for Iron Sucrose Injection, USP - ACCESS Newswire
18,358 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Purchased by XTX Topco Ltd - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Up 12.1%Here's Why - MarketBeat
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates - MSN
Utah Medical Products Reports Q2 Decline - AOL.com
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $25.00 by Analysts at Piper Sandler - MarketBeat
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q2 2025 Earnings Call Transcript - Insider Monkey
Pfizer beats in Q2 earnings, reaffirms 2025 outlook [Video] - AOL.com
Interpace Biosciences Earnings Drop - AOL.com
Amphastar Pharmaceuticals Inc (AMPH) Q2 2025 Earnings Call Highlights: Strong Vaccine Sales and ... By GuruFocus - Investing.com Canada
Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells 500 Shares of Stock - MarketBeat
Amphastar 2025 Q2 Earnings Net Income Falls 18.2% Amid Revenue Decline - AInvest
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now? - Yahoo Finance
Piper Sandler lowers Amphastar Pharmaceuticals stock price target on competitive headwinds - Investing.com Canada
Earnings call transcript: Amphastar Q2 2025 beats EPS forecast, stock rises - Investing.com Canada
Amphastar August 2025 presentation slides: long-term growth strategy faces near-term headwinds - Investing.com Canada
Amphastar Pharmaceuticals Topped Earnings And Is Doubling Down At Home - Finimize
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q2 Sales Targets, But Stock Soars 6% - Yahoo Finance
Atea (AVIR) Q2 Loss Narrows 8% - AOL.com
Amphastar advances U.S. manufacturing expansion and signals flat 2025 revenue outlook amid competitive pressures - MSN
Amphastar's Q2 2025: Unpacking Contradictions in BAQSIMI Growth, Manufacturing Capacity, and FDA Approvals - AInvest
Amphastar Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:AMPH) - Seeking Alpha
Amphastar Pharmaceuticals Reports Q2 2025 Earnings Highlights - TipRanks
Amphastar Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Amphastar (AMPH) Q2 2025 Earnings Call Transcript - AOL.com
Amphastar (AMPH) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Amphastar: Q2 Earnings Snapshot - San Francisco Chronicle
Amphastar Pharma Q2 revenue beats estimates - MarketScreener
Earnings Flash (AMPH) Amphastar Pharmaceuticals, Inc. Reports Q2 Revenue $174.4M, vs. FactSet Est of $174.0M - MarketScreener
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025 - ACCESS Newswire
Immunocore (IMCR) Q2 Revenue Jumps 30% - AOL.com
AstraZeneca increasing focus on US market, as it is 'first to provide access to patients': CFO [Video] - AOL.com
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 1-Year LowWhat's Next? - MarketBeat
Amphastar Pharmaceuticals (AMPH) Reports Q2: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
4.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):